Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
152 participants
OBSERVATIONAL
2022-03-23
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OptiMEDs Pilot Study
NCT04142645
Optimising Pharmacist-led Medication Reviews in Primary Care
NCT05928104
Deprescribing in a Long Term Care Facility
NCT03091153
Impact of the Intervention of Pharmacists and Geriatrician on Drug Prescription in Elderly Patients in a Surgical ICU
NCT03706092
Improved Prescribing for Older Nursing Home Patients
NCT06731361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, an under investigated area of prescribed medicines is the views of people living in care homes, health and social care staff, commissioners and regulator about managing medicines in care homes.
During the study a series of semi-structured interviews and focus groups will be undertaken. These focus groups will be held with people living in care homes (with and without nursing). Further interviews and focus groups will be held with health and social care staff, commissioners and regulators.
Care homes will be invited to provide copies of their current medicines monitoring tool. In addition, services supporting care homes including community pharmacies will also be invited to provide copies of their current medicines monitoring tools.
Analysis of conversations and monitoring tools made available to the study team will be undertaken and compared to published literature including grey literature.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Qualitative interviews and focus group
Qualitative semi-structured individual interviews and focus groups to be held with people living in care homes (with and without nursing), health and social care staff supporting these people, commissioners and regulators.
Interview or focus group discussion
There is no intervention. This is a qualitative piece of work only
Qualitative medicines monitoring tools
Submission of current medicines monitoring tools by care homes and services supporting care homes including community pharmacies.
Review of submitted medicines audit tools
There is no intervention. This is a qualitative piece of work only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview or focus group discussion
There is no intervention. This is a qualitative piece of work only
Review of submitted medicines audit tools
There is no intervention. This is a qualitative piece of work only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* within pre-agreed areas,
* registered with the regulator (CQC) for the regulated activities of Residential Care (with or without nursing) that have consented to participate.
* Theses care homes will also be registered for one or more of the following specialisms:
* dementia,
* mental health conditions,
* physical disabilities,
* sensory impairments,
* caring for adults under 65 years
* caring for adults over 65 years.
2. Residents who have capacity and an adequate understanding of written and verbal English to consent and participate of participating care homes.
3. Care home staff, including registered managers who have an adequate understanding of written and verbal English to consent and participate of participating care homes.
4. Visiting health and social care staff who support care homes in the study locality.
5. Commissioner and regulatory staff with oversight of care homes in the study locality.
6. Medicines monitoring tools used by participating
* care homes,
* community pharmacies supporting the participating care homes
* commissioners and regulators with oversight of care homes in the study locality.
Exclusion Criteria
* outside of the pre-agreed areas.
2. Care homes registered with the regulator (CQC)
* within the pre-agreed areas for the regulated activities of Residential Care (with or without nursing) that are also registered for the specialism of supporting younger people.
3. Residents of participating care homes judged by staff to lack capacity, an adequate understanding of written and verbal English to consent and participate, too unwell or might find it distressing.
4. Staff in participating care homes who lack an adequate understanding of written and verbal English to consent and participate.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Central Lancashire
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Malcolm Irons
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malcolm W Irons
Role: PRINCIPAL_INVESTIGATOR
University of Central Lancashire
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Central Lancashire
Preston, Lancashire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
280907
Identifier Type: OTHER
Identifier Source: secondary_id
21/IEC08/0015
Identifier Type: OTHER
Identifier Source: secondary_id
HEALTH 0228CA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.